Keeping Track: FDA Clears Motegrity And Second Herceptin Biosimilar, But Rebuffs SpecGx's Oxycodone

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

The clock is just two weeks away from striking midnight on 2018, and the final drug development announcements from sponsors are trickling in. Here's your news in brief:

The US FDA approved the year's 56th novel drug with the green light for Shire PLC's Motegrity (prucalopride), designed...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet